David J. Grainger - Feb 1, 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Innovation Officer
Signature
/s/ Marella Thorell, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 05:30 PM
Previous filing
Feb 1, 2022
Next filing
Jul 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Award $0 +200K $0.00 200K Feb 1, 2022 Ordinary Shares 200K $9.53 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 33,328 shares subject to such option shall vest and become exercisable on October 1,2022 and the remaining 166,672 shares subject to such option shall vest and become exercisable in 40 substantially equal installments on each monthly anniversary thereafter.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.